Drug Discoveries: Translation to disease management protocols for patients скачать в хорошем качестве

Drug Discoveries: Translation to disease management protocols for patients

Ira Pastor ideaXme longevity and aging ambassador and founder of Bioquark interviews John LaMattina, Senior Partner PureTech Health and former President of R&D Pfizer. They talk of drug discoveries and treatments and the process of translating them to disease management protocols for patients. Ira Pastor ideaXme longevity and aging ambassador and John LaMattina Partner PureTech Ira Pastor comments: On the last several shows, we have spent time on the different hierarchical levels of the aging process and diseases of aging – from the genome, to tissue level physiologic networks, to the microbiome, to the human organism’s interaction with its external micro-environment. Translating drug discoveries: However, exciting as all these scientific disciplines are, it all boils down to one thing – proper translation of these discoveries towards registrational and commercializable interventions that clinicians can prescribe and patients can make part of their disease management protocols. Today’s guest is an expert’s expert in translatable drug development. Drug discoveries. Patient protocols at Pfizer: Dr. John LaMattina, PhD in organic chemistry, climbed the ladder of big pharma to become President of Pfizer’s global R&D organization, where he managed more than 13,000 scientists and professionals in the United States, Europe, and Asia. John LaMattina, Partner PureTech Health He was responsible for many of its” blockbusters” including Lipitor, Viagra, Zoloft, Zithromax, Celebrex, Aricept, Diflucan, and Norvasc which turned Pfizer into the $50+ billion mega-pharma organization. Drug discoveries and health tech at PureTech Health: After Pfizer he moved into the venture capital world as a senior partner at PureTech Health sitting on the board of many start-up and development phase companies in the biotech and health tech space He’s the author of several books including “Drug Truths: Dispelling The Myths Of R&D” and the recently published “Devalued And Distrusted: Can The Pharmaceutical Industry Restore Its Broken Image?” – He is also a routine contributor to Forbes magazine. In this interview we hear from Dr. LaMattina about drug discovery and the paths to disease management protocols for patients. About his background, how he became interested in science, in particular pharma. Furthermore, we hear of his journey to the top of one of the world’s largest drug companies. Drug discoveries for rare disease and large populations: His thoughts on the future of blockbuster drugs versus personalized medicines and more targeted approaches for smaller patient populations, rare, orphan diseases. John LaMattina, Partner PureTech Health: His analysis of anti-aging medicine and how Alzheimers will be one of mankind’s key challenges as the average lifespan increases. His opinion on FDA approval of non-traditional drug discoveries. His call to action to combat obesity, the cause of major illnesses in humans. See CDC website reporting on obesity statistics in the USA. Legislation for drug discoveries: His views on the legislative front and proper ways for speeding up access to development stage drug candidates for “no-option” dying patients. Towards the end of the interview discover whom John LaMattina would like to meet and what he’d like to discover in journeying to the future. Credits: Ira Pastor interview text and audio. Ira Pastor founder Bioquark and ideaXme Longevity and Aging ambassador Twitter: @John_LaMattina @IraSamuelPastor @ideaxm If you enjoy this interview you may like Pain control in a post opioid world. ideaXme is a podcast, ambassador and mentor programme. Our mission is to Move the human story forward! Our interviews with the innovators and creators who shape our world are published across the web including iTunes, SoundCloud, Spotify, Radio Public and TuneIn Radio. For links relating to this interview: www.radioideaxme.com